| abstract |
The present disclosure provides improved genome editing compositions and methods for editing the CBLB gene. The disclosure further provides a genome-edited cell for the prevention, treatment, or alleviation of at least one symptom of cancer, infectious disease, autoimmune disease, inflammatory disease, or immunodeficiency. In various embodiments, the present disclosure contemplates, in part, a polypeptide that includes a homing endonuclease (HE) variant that cleaves a target site within the human CBLB gene. [Selection diagram] Figure 1 |